Pakistan’s pharmaceutical sector has achieved 34% growth in exports during the fiscal year ended June 30, 2025, reaching $457 million. This surge marks the highest growth in two decades and places pharmaceuticals among the country’s fastest-growing export categories.
The previous year, pharmaceutical exports were recorded at $341 million. The growth is the most significant since 2009, when exports grew by 32%.
Therapeutic goods, including pharmaceuticals, surgicals, food supplements, medical devices, and nutraceuticals, also registered significant export figures, totaling $909 million in FY25, just $91 million short of the $1 billion mark.
The Pakistan Pharmaceutical Manufacturers’ Association (PPMA) attributed the 34% export growth to favourable government pricing policies. The association noted that the deregulation of non-essential medicines in February 2024 allowed pharmaceutical firms to focus on exports, adjust for inflation, invest in production, and curb black-market sales.
The deregulation also encouraged foreign pharmaceutical companies to invest further in Pakistan, leading to a positive outlook for long-term market stability.
